Loading...
Loading...
ACHL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.3M |
| Gross Profit | -1.3M |
| Operating Expense | 18.1M |
| Operating I/L | -18.1M |
| Other Income/Expense | 1.2M |
| Interest Income | 0.0M |
| Pretax | -16.9M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -16.8M |
Achilles Therapeutics Plc is a clinical stage immuno-oncology biopharmaceutical company specializing in precision T cell therapies for solid tumors. Its lead product candidates, CHIRON and THETIS, are in Phase I/IIa clinical trials for treating advanced non-small cell lung cancer and metastatic or recurrent melanoma, respectively. The company is also developing therapies for head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer.
